Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Patients with cystic fibrosis frequently develop chronic rhinosinusitis. Bacterial
colonization is facilitated by a reduced mucociliary function and some previous studies
suggest that the microbiology of the upper airways might influence the microbiology of the
lower airway. The aim of this randomized control study is to demonstrate efficacy of
antibiotic delivered by nebulized sonic aerosol therapy to decrease the bacterial load in
sinuses and medium ostia and to improve the sino-nasal symptoms and endoscopic scores,
quality of life and lung function